https://peptide.zone/story/tradipitant-glp-1-vomiting-phase-3Peptide Zoneen2026-10-28T15:25:00.000ZTradipitant GLP 1 vomiting trial reports 27 percent relative drop in Phase 3 https://peptide.zone/story/glp-1-naion-lawsuits-vision-loss-evidencePeptide Zoneen2026-10-28T15:22:00.000ZGLP 1 NAION lawsuits move ahead as vision loss evidence stays split https://peptide.zone/story/awiqli-pediatric-approval-weekly-insulin-childrenPeptide Zoneen2026-10-28T14:36:00.000ZFDA grants Awiqli pediatric approval as first weekly insulin for children with type 2 diabetes https://peptide.zone/story/retatrutide-sleep-apnea-phase-3-trialsPeptide Zoneen2026-10-28T14:12:00.000ZRetatrutide sleep apnea trials cut breathing pauses in Phase 3 NEJM report https://peptide.zone/story/glp-1-eating-disorder-screening-evidencePeptide Zoneen2026-10-28T13:25:00.000ZGLP 1 Eating Disorder Screening Gains Backing as Binge Eating Evidence Stays Thin https://peptide.zone/story/employer-glp-1-coverage-stalls-kff-surveyPeptide Zoneen2026-10-27T15:51:00.000ZEmployer GLP 1 coverage for weight loss stalls at 18 percent in KFF survey https://peptide.zone/story/wada-2027-prohibited-list-glp-1-permittedPeptide Zoneen2026-10-27T15:41:00.000ZWADA 2027 Prohibited List keeps semaglutide and tirzepatide permitted for athletes https://peptide.zone/story/peptide-injectors-needle-programs-safety-advicePeptide Zoneen2026-10-27T14:58:00.000ZPeptide injectors need needle programs and safety advice say Queensland researchers https://peptide.zone/story/topical-icotrokinra-preclinical-psoriasis-dataPeptide Zoneen2026-10-27T14:22:00.000ZDong A ST presents topical icotrokinra data from early skin and animal tests